Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys $189,222.75 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 7,803 shares of Sensei Biotherapeutics stock in a transaction dated Tuesday, June 30th. The shares were bought at an average cost of $24.25 per share, for a total transaction of $189,222.75. Following the completion of the acquisition, the chief financial officer owned 41,688 shares in the company, valued at $1,010,934. This represents a 23.03% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ FTH opened at $22.92 on Friday. Sensei Biotherapeutics, Inc. has a 52 week low of $6.32 and a 52 week high of $36.76.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, research analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on FTH shares. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. HC Wainwright assumed coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 target price for the company. Finally, Robert W. Baird began coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.